About Randox
You may recognise Randox as the principal sponsor of the world’s most famous steeplechase, the Randox Grand National or as the Team GB Official Diagnostic Health partners ahead of the upcoming Olympics, but for forty years Randox have been focusing on the provision of timely and accurate diagnostic testing and promotion of preventative healthcare.
Disruptive Innovation in Diagnostics and Healthcare
Randox’s proprietary Biochip Technology, the result of a £350 million investment, allows many tests to be run simultaneously, which greatly improves he diagnostic power available to clinicians.
Randox’s diagnostic focus is to undertake comprehensive testing and data analysis to identify risk to health, promote preventative healthcare and improve clinical diagnosis. Aiming to achieve better healthcare outcomes whilst reducing the burden on healthcare services.
Whilst the science is complex, the applications are not. Diagnostic testing takes place every day behind the scenes of GP surgeries, laboratories and hospitals.
Around 70% of all medical decisions are based on laboratory results, and so, not surprisingly, we believe that earlier, more accurate and more accessible diagnostics are the key to improving global health and saving lives.
The Future of Healthcare
We are significantly increasing our UK High Street presence, using the unique national coronavirus testing infrastructure and capacity we invested in during the pandemic to deliver a new range of preventative health checks. Expansion plans will see up over 20 new Randox Health clinics operating in the UK and Northern Ireland by the end of the year. The clinics will provide easy access for millions to a range of diagnostic tests for vitamin deficiencies, hormone imbalances, inherited/genetic conditions and key health concerns including heart, liver and kidney conditions.
Key to the unique range of diagnostic testing available at our growing network of clinics is the testing technologies, facilities and comprehensive, nationwide distribution network rapidly developed by Randox Laboratories to play a key role in meeting the sudden national demand for Covid-19 PCR tests. At the height of the pandemic emergency, Randox were the only laboratory in the UK and Northern Ireland to process over 100,000 PCR tests per day, saving thousands of lives.
Now, with millions of people having become accustomed to regular testing through the pandemic, Randox is combining that familiarity with its own unique Covid-19 experience and infrastructure to deliver real, affordable and preventative healthcare through early diagnostic testing on the High Street.
“Randox believes that in harnessing the achievements of during the pandemic we can help the shift away from the traditional model of sickness management to a new era of truly preventative healthcare. This will benefit individuals and society by improving patient outcomes and considerably reducing the burden on our vital and hard-pressed clinical services” (Randox founder and Managing Director – Dr Peter FitzGerald).
Frequently Asked Questions?
What is the vision of Randox?
The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.
We have also spent more than £220 million developing our patented Randox Biochip. This state-of-the-art biochip technology has revolutionised the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.
When and why was Randox established?
Our Managing Director Dr FitzGerald established Randox in 1982 in County Antrim, Northern Ireland, to address the need for accurate and readily available diagnostic tests to improve patient diagnosis. At that time, doctors only conducted a handful of tests per patient, but now, more than 40 years later, Randox has developed and improved hundreds of tests, with hundreds more in development.
What products and service do Randox offer?
Randox has a broad range of products and services that offer a comprehensive insight into patient diagnosis to facilitate more effective disease management and treatment.
Our clinical product offering includes diagnostic reagents, quality control, and clinical chemistry analysers.
Our patented Randox Biochip Technology and associated Immunoassay analysers also have applications for forensic toxicology, food diagnostics, and workplace drug testing.
Our Randox Health clinics offer a range of health checks across general health, sexual health, respiratory health and more.
Who and where are Randox customers?
Randox’s focus has traditionally been on healthcare providers, so we have placed our products and services in hospitals, clinics, research and molecular laboratories, food testing, forensic toxicology, life sciences and veterinary laboratories.
With the establishment of our consumer brand, Randox Health, we also offer our innovative tests directly to the consumer in our Randox Health clinics, located across the UK including London, Liverpool, Manchester, Birmingham, Glasgow, Edinburgh, Holywood and Crumlin.
We have ambitious plans to roll out a number of new clinics across the United Kingdom and internationally, over the coming months and years.
What is the size of the company?
Our company has grown from a small team of two scientists, to over 3300 employees of 44 nationalities, including 650 research scientists and engineers.
Where are Randox headquartered and what is the geographical reach?
Our headquarters are in Crumlin, in County Antrim, Northern Ireland – close to Belfast International Airport. However, we are a global company and currently have offices and distribution outlets in 145 countries, with manufacturing and R&D capabilities in 4 jurisdictions across 3 continents.
We are currently relocating our headquarters to the Randox Science Park in Antrim; a £161 million project which will accelerate the development of new products into a wide range of clinical needs, including various cancers, stroke, heart disease and neurodegenerative disorders.
We are very proud of our global penetration – today, approximately 5% of the world’s population receives medical diagnoses using products from Randox. That equates to about 400 million people. We also supply 15% of the world’s cholesterol tests, so if you’ve ever had your cholesterol checked, then there’s a high chance it could have been performed using a Randox product!
What are the biggest issues within the health sector?
Our key observation across the globe is that within healthcare the pressure on resources means there is a focus on the “management of sickness,” rather than preventative care.
We know that a focus on early diagnosis and preventative care will improve patient outcomes and reduce the burden on healthcare systems. Making that paradigm shift is a major challenge.
That’s why Randox Health was established – to allow the consumer direct access to our innovative technologies so that they can take control of their health and make appropriate lifestyle changes BEFORE disease manifests and symptoms occur.
Want to know more?
Contact us or visit our dedication to quality webpage.